Comparison of Nonsequencing Techniques for Identification of NPM1 Mutations and Associated Blast Morphology in Patients With Acute Myeloid Leukemia

被引:1
|
作者
Menegotto, Pamela Rossi [1 ,2 ]
Farias, Mariela Granero [5 ]
Spagnol, Fabiane [5 ]
Siebert, Marina [3 ,6 ,7 ]
Filippi-Chiela, Eduardo Cremonese [4 ,7 ]
Alegretti, Ana Paula [5 ]
Pilger, Diogo Andre [1 ,2 ,8 ]
机构
[1] Univ Fed Rio Grande do Sul, Fac Farm, Dept Anal, Lab Andlises Bioquim & Citol, Porto Alegre, Brazil
[2] Univ Fed Rio Grande do Sul, Postgrad Programs Pharmaceut Sci, Porto Alegre, Brazil
[3] Univ Fed Rio Grande do Sul, Gastroenterol & Hepatol, Porto Alegre, Brazil
[4] Univ Fed Rio Grande do Sul, Morphol Sci Dept, Porto Alegre, Brazil
[5] Hosp Clin Porto Alegre, Unidade Diagnost Especializado, Porto Alegre, Brazil
[6] Hosp Clin Porto Alegre, Basic Res & Adv Invest Neurosci Lab, Porto Alegre, Brazil
[7] Hosp Clin Porto Alegre, Expt Res Ctr, Porto Alegre, Brazil
[8] Univ Fed Rio Grande Sul UFRGS, Fac Farm, Lab Anal Bioquim & Citol, Av Ipiranga 2752, BR-90610000 Porto Alegre, Brazil
关键词
ACUTE MYELOGENOUS LEUKEMIA; WORLD-HEALTH-ORGANIZATION; NPM1; MUTATIONS; CYTOPLASMIC NUCLEOPHOSMIN; TANDEM DUPLICATION; GENE; CLASSIFICATION; PREVALENCE; NEOPLASMS; DIAGNOSIS;
D O I
10.5858/arpa.2021-0601-OA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
center dot Context.-Nucleophosmin 1 (NPM1) mutations affect 20% to 30% of all acute myeloid leukemia (AML) patients; several methods are employed to analyze NPM1 muta-tions, each of them with its advantages and limitations.Objective.-To compare 3 nonsequencing protocols capable of detecting the main NPM1 mutations and to evaluate nuclear morphometric analysis (NMA) as an alternative to cuplike blast detection.Design.-We selected multiparameter flow cytometry (MFC), amplification refractory mutation system-polymer-ase chain reaction (ARMS-PCR), and a quantitative PCR (qPCR) kit to identify NPM1 mutations in AML patients at diagnosis. We also evaluated the presence of cuplike blasts and assessed nuclear morphometry using NMA.Results.-MFC appears as a screening method for NPM1 mutations because of its lower specificity. ARMS-PCR demonstrated specificity similar to that of the qPCR kit, although it was more laborious. qPCR testing, conversely, is relatively fast and easy to standardize. Of these methods, qPCR was the only one capable of identifying the type of NPM1 mutation. With regard to morphology, NMA could be used as an alternative for the evaluation of cuplike blasts in AML smears.Conclusions.-qPCR appears to be the best option to identify NPM1 mutations, with ARMS-PCR representing a cheaper alternative. MFC may be used as a screening method, in which results falling within and above the gray zone should be confirmed by molecular testing.(Arch Pathol Lab Med. 2023;147:701-709; doi: 10.5858/ arpa.2021-0601-OA)
引用
收藏
页码:701 / 709
页数:9
相关论文
共 50 条
  • [21] Acute myeloid leukemia with concurrent NPM1 and RUNX1 mutations
    Zuo, Zhuang
    Medeiros, L. Jeffrey
    Yin, C. Cameron
    LEUKEMIA RESEARCH REPORTS, 2023, 20
  • [22] NPM1 Mutations Are a Secondary Genetic Event in NPM1-Mutated Acute Myeloid Leukemia
    Patel, Jay L.
    Schumacher, Jonathan
    Szankasi, Philippe
    Frizzell, Kimberly
    Sorrells, Shelly
    Shen, Wei
    Clayton, Adam
    Jattani, Rakhi
    Kelley, Todd W.
    MODERN PATHOLOGY, 2017, 30 : 369A - 369A
  • [23] NPM1 Mutations Are a Secondary Genetic Event in NPM1-Mutated Acute Myeloid Leukemia
    Patel, Jay L.
    Schumacher, Jonathan
    Szankasi, Philippe
    Frizzell, Kimberly
    Sorrells, Shelly
    Shen, Wei
    Clayton, Adam
    Jattani, Rakhi
    Kelley, Todd W.
    LABORATORY INVESTIGATION, 2017, 97 : 369A - 369A
  • [24] Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia
    Leibundgut, Elisabeth Oppliger
    Porret, Naomi A.
    Muggli, Marianne Bienz
    Baumgartner, Heidi
    Dahlhaus, Meike
    Baerlocher, Gabriela M.
    ANNALS OF HEMATOLOGY, 2013, 92 (02) : 173 - 177
  • [25] Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia
    Suzuki, T
    Kiyoi, H
    Ozeki, K
    Tomita, A
    Yamaji, S
    Suzuki, R
    Kodera, Y
    Miyawaki, S
    Asou, N
    Kuriyama, K
    Yagasaki, F
    Shimazaki, C
    Akiyama, H
    Nishimura, M
    Motoji, T
    Shinagawa, K
    Takeshita, A
    Ueda, R
    Kinoshita, T
    Emi, N
    Naoe, T
    BLOOD, 2005, 106 (08) : 2854 - 2861
  • [26] Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
    Mariotti, Benedetta
    Meconi, Federico
    Palmieri, Raffaele
    De Bellis, Eleonora
    Lavorgna, Serena
    Ottone, Tiziana
    Martini, Vincenza
    Lo-Coco, Francesco
    Cicconi, Laura
    CASE REPORTS IN HEMATOLOGY, 2019,
  • [27] Analysis of NPM1 gene mutations in Chinese adults with acute myeloid leukemia
    Yan, Lingzhi
    Chen, Suning
    Liang, Jianying
    Feng, Yufeng
    Cen, Jiannong
    He, Jun
    Chang, Weirong
    Zhu, Ziling
    Pan, Jinlan
    Wu, Yafang
    Xue, Yongquan
    Wu, Depei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 86 (02) : 143 - 146
  • [28] Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia
    Elisabeth Oppliger Leibundgut
    Naomi A. Porret
    Marianne Bienz Muggli
    Heidi Baumgartner
    Meike Dahlhaus
    Gabriela M. Baerlocher
    Annals of Hematology, 2013, 92 : 173 - 177
  • [29] MUTATIONS OF RECEPTOR TYROSINE KINASE AND NPM1 GENES IN ACUTE MYELOID LEUKEMIA
    Zaker, F.
    Mohammadzadeh, M.
    Mohammadi, M.
    Pazhakh, V.
    Kazemi, A.
    Alimoghadam, K.
    EXPERIMENTAL HEMATOLOGY, 2010, 38 (09) : S18 - S19
  • [30] NPM1 AND FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
    Aguiar, E.
    Amorim, M.
    Gomes, M. P.
    Guimaraes, P.
    Trigo, F.
    Guimaraes, J. E.
    HAEMATOLOGICA, 2012, 97 : 507 - 508